文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

108600 同时抑制 CK2/TNIK/DYRK1，抑制三阴性乳腺癌干细胞和化疗耐药性疾病。

Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.

机构信息

Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

Nat Commun. 2021 Aug 3;12(1):4671. doi: 10.1038/s41467-021-24878-z.

DOI:10.1038/s41467-021-24878-z
PMID:34344863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8333338/
Abstract

Triple negative breast cancer (TNBC) remains challenging because of heterogeneous responses to chemotherapy. Incomplete response is associated with a greater risk of metastatic progression. Therefore, treatments that target chemotherapy-resistant TNBC and enhance chemosensitivity would improve outcomes for these high-risk patients. Breast cancer stem cell-like cells (BCSCs) have been proposed to represent a chemotherapy-resistant subpopulation responsible for tumor initiation, progression and metastases. Targeting this population could lead to improved TNBC disease control. Here, we describe a novel multi-kinase inhibitor, 108600, that targets the TNBC BCSC population. 108600 treatment suppresses growth, colony and mammosphere forming capacity of BCSCs and induces G2M arrest and apoptosis of TNBC cells. In vivo, 108600 treatment of mice bearing triple negative tumors results in the induction of apoptosis and overcomes chemotherapy resistance. Finally, treatment with 108600 and chemotherapy suppresses growth of pre-established TNBC metastases, providing additional support for the clinical translation of this agent to clinical trials.

摘要

三阴性乳腺癌（TNBC）由于对化疗的反应不一致而仍然具有挑战性。不完全反应与转移性进展的风险增加相关。因此，针对化疗耐药性 TNBC 并增强化疗敏感性的治疗方法将改善这些高危患者的预后。乳腺癌干细胞样细胞（BCSCs）被认为代表了一种化疗耐药亚群，负责肿瘤的起始、进展和转移。针对该群体可能会导致 TNBC 疾病控制得到改善。在这里，我们描述了一种新型多激酶抑制剂 108600，它针对 TNBC BCSC 群体。108600 治疗抑制 BCSC 的生长、集落和类器官形成能力，并诱导 TNBC 细胞的 G2M 期阻滞和凋亡。在体内，用 108600 治疗携带三阴性肿瘤的小鼠可诱导细胞凋亡并克服化疗耐药性。最后，用 108600 和化疗联合治疗可抑制已建立的 TNBC 转移的生长，为将该药物转化为临床试验提供了更多支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/e1251a8866b7/41467_2021_24878_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/787f910e9254/41467_2021_24878_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/c2026dcd4646/41467_2021_24878_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/a0979e70e040/41467_2021_24878_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/be67a4b7dffb/41467_2021_24878_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/f89c119bb59c/41467_2021_24878_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/f14d8971a573/41467_2021_24878_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/e1251a8866b7/41467_2021_24878_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/787f910e9254/41467_2021_24878_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/c2026dcd4646/41467_2021_24878_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/a0979e70e040/41467_2021_24878_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/be67a4b7dffb/41467_2021_24878_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/f89c119bb59c/41467_2021_24878_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/f14d8971a573/41467_2021_24878_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93c/8333338/e1251a8866b7/41467_2021_24878_Fig7_HTML.jpg

相似文献

[1]
Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.

Nat Commun. 2021-8-3

[2]
Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.

Breast Cancer. 2017-9

[3]
Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.

Oncogene. 2020-9-14

[4]
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.

Br J Cancer. 2018-11-28

[5]
A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.

Breast Cancer Res. 2019-7-1

[6]
Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.

Int J Oncol. 2018-1-15

[7]
The GEF-H1/PKD3 signaling pathway promotes the maintenance of triple-negative breast cancer stem cells.

Int J Cancer. 2020-6-15

[8]
IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells.

Cell Oncol (Dordr). 2024-10

[9]
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.

PLoS One. 2019-11-21

[10]
Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.

Breast Cancer Res Treat. 2015-6

引用本文的文献

[1]
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances.

Signal Transduct Target Ther. 2025-4-4

[2]
Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism.

Nat Commun. 2025-2-1

[3]
A safe haven for cancer cells: tumor plus stroma control by DYRK1B.

Oncogene. 2025-2

[4]
Losartan-based nanocomposite hydrogel overcomes chemo-immunotherapy resistance by remodeling tumor mechanical microenvironment.

J Nanobiotechnology. 2024-10-30

[5]
Therapeutic targeting of TNIK in papillary thyroid carcinoma: a novel approach for tumor growth suppression.

Med Oncol. 2024-5-20

[6]
Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.

Pharmaceutics. 2024-4-11

[7]
TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy.

Mol Cancer Ther. 2024-4-27

[8]
CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer.

Cell Death Discov. 2024-4-22

[9]
A Compact Reprogrammed Genetic Code for De Novo Discovery of Proteolytically Stable Thiopeptides.

J Am Chem Soc. 2024-3-27

[10]
depletion induces inflammation and apoptosis in injured renal proximal tubule epithelial cells.

Am J Physiol Renal Physiol. 2024-5-1

本文引用的文献

[1]
Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC.

Adv Exp Med Biol. 2019

[2]
Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.

Oncotarget. 2018-12-28

[3]
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

Cancer Discov. 2019-1-24

[4]
Self-renewal signaling pathways in breast cancer stem cells.

Int J Biochem Cell Biol. 2018-12-26

[5]
Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice.

Cancer Res. 2018-8-23

[6]
Identification of Candidate Casein Kinase 2 Substrates in Mitosis by Quantitative Phosphoproteomics.

Front Cell Dev Biol. 2017-11-22

[7]
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

Nat Rev Clin Oncol. 2017-10

[8]
Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).

Medicine (Baltimore). 2017-4

[9]
Inhibition of casein kinase 2 blocks G/M transition in early embryo mitosis but not in oocyte meiosis in mouse.

J Reprod Dev. 2017-6-21

[10]
Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.

J Neurooncol. 2017-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索